A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma. READ MORE
Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse.
Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival as younger patients.
Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT.
Lenalidomide maintenance therapy after autologous stem-cell transplantation prolongs the time to remission in patients with multiple myeloma.